

Acuti Martellucci Cecilia (Orcid ID: 0000-0002-4308-2144)
Baccolini Valentina (Orcid ID: 0000-0002-7873-7817)
Manzoli Lamberto (Orcid ID: 0000-0002-8129-9344)

Title: Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis.

Running title: SARS-CoV-2 reinfection after prior infection.

Authors: Maria Elena Flacco * (1), Cecilia Acuti Martellucci * (1), Valentina Baccolini (2), Corrado De Vito (2), Erika Renzi (2), Paolo Villari (2), Lamberto Manzoli (3).

Affiliations:

- (1) Department of Environmental and Preventive Sciences, University of Ferrara, Italy;
- (2) Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy;
- (3) Department of Medical and Surgical Sciences, University of Bologna, Italy;

Corresponding author: Lamberto Manzoli, lmanzoli@post.harvard.edu; Tel.: +39-3474727282

Word count: 2731.

* These authors equally contributed to the present work.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/eci.13845](https://doi.org/10.1111/eci.13845)

This article is protected by copyright. All rights reserved.

Abstract

Introduction: A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection.

Methods: We searched MedLine, Scopus and preprint repositories for cohort studies evaluating the onset of new infections among baseline SARS-CoV-2-positive subjects. Random-effect meta-analyses of proportions were stratified by gender, exposure risk, vaccination status, viral strain, time between episodes, and reinfection definition.

Results: Ninety-one studies, enrolling 15,034,624 subjects, were included. Overall, 158,478 reinfections were recorded, corresponding to a pooled rate of 0.97% (95% CI: 0.71%-1.27%), with no substantial differences by definition criteria, exposure risk or gender. Reinfection rates were still 0.66% after ≥ 12 months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3 months of Omicron wave, the reinfection rates reached 3.31%. Overall rates of severe/lethal COVID-19 were very low (2-7 per 10,000 subjects according to definition criteria), and were not affected by strain predominance.

Conclusions: A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and healthcare needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low. The risk-benefit profile of multiple vaccine doses for this subset of population needs to be carefully evaluated.

Key words: SARS-CoV-2; COVID-19; reinfection; meta-analysis; Omicron variant.

Introduction

After the first documented case on August 2020 in Hong-Kong ¹, an increasing number of field studies estimated the rate of SARS-CoV-2 reinfections after a primary episode ²⁻²⁷. Although the reported rates have been consistently low, the results differed according to the adopted definition of reinfection, setting, pandemic period, follow-up duration, and uncertainties remain on the risk of developing a severe COVID-19 disease after a reinfection ^{17,20,28}. Moreover, the rapid spread of the SARS-CoV-2 Omicron variant (B.1.1.529) ²⁹ has posed additional concerns on the degree of protection conferred by prior infections ^{30,31}.

As a precise estimate of the frequency and severity of reinfections would be critical to predict the course of the pandemic and optimize restriction and vaccination policies for the hundreds of millions of subjects who recovered from a SARS-CoV-2 infection ³²⁻³⁴, we carried out a meta-analysis of the available prospective observational evidence to provide a pooled estimate of the risk of SARS-CoV-2 reinfection, and severe and lethal COVID-19. Reinfection rates were also computed separately for each gender, exposure risk, vaccination coverage, definitions of reinfection, and predominant viral strain.

Methods

The reporting of this meta-analysis was guided by the standards of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 Statement ³⁵. We extracted data from cohort studies evaluating the onset of a new SARS-CoV-2 infection (either asymptomatic or symptomatic) among subjects of all ages with a prior positive SARS-CoV-2 baseline status.

We searched MedLine and Scopus databases, up to June 30, 2022, using the following search strategy, without language restrictions: (coronavirus* or coronovirus* or coronavirinae* or Coronavirus* or Coronovirus* or Wuhan* or Hubei* or Huanan or "2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCov or "HCoV-19" or HCoV19 or CoV or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncover or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese*) AND (reinfection* or re-infection* or second episode or recurrence* or recrudescence* or relapse* or RCOVID19) ³⁶. The references of the reviews and retrieved articles were also screened for additional pertinent papers. Given that several relevant clinical databases have been shared in public preprint repositories in the context of a public health emergency, we also searched for potential studies among those submitted in medRxiv.org ³⁷. In case of re-analyses published from the same cohort, we extracted the data of the publication with the longer follow-up or, if the length of follow-up was identical, with the largest sample size.

Each included article was independently evaluated by three reviewers (CAM, VB and ER), who extracted the main study characteristics (first author, publication year, study design, population, overall sample, mean age and gender distribution of the participants, length of follow-up, dominant variant, vaccination coverage (if

underway), protocol of evaluation of SARS-CoV-2 (re)infection, minimum time-lag between primary and secondary positive episodes) and the raw numbers of: (a) SARS-CoV-2 reinfections (asymptomatic infections or mild diseases, with fever or malaise plus at least one of the followings: sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis, and diarrhea with no hospital admission); (b) severe COVID-19 diseases (requiring hospital admission with no use of an intensive care unit); (c) subjects with very severe/lethal COVID-19 disease (requiring admission in an intensive care unit and/or causing death) ¹¹. In case of discrepancies in data extraction, a fourth author was contacted (MEF), and consensus achieved through discussion.

The first infection was defined by the presence of: (a) a positive reverse-transcriptase polymerase chain reaction (RT-PCR) test; and/or (b) a baseline positive serology, investigated with the use of an anti-trimeric spike IgG enzyme-linked immunosorbent assay (ELISA) ³⁸.

In accordance with the CDC criteria ³⁹, a reinfection was defined by the presence of:

- (a) two positive PCR samples detected ≥ 45 days apart with ≥ 1 negative RT-PCR test collected between the first and second episode ⁴⁰, and/or confirmation of infection with two different phylogenetic strains by viral genomic sequencing ²⁸;
- (b) two positive PCR samples detected ≥ 45 days apart in subjects with a symptomatic second episode or in close contact with a laboratory-confirmed COVID-19 case ³⁹;
- (c) a positive PCR test ≥ 45 days after the first positive serology (detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay - ELISA) ^{38,39}.

When a study adopted a time-lag between two positive episodes < 45 days, we conservatively extracted and included only the cases with a new positive RT-PCR occurring ≥ 45 days after the first episode, unless other evidences of reinfection (negative PCR or different genome sequence) were available.

We used random-effect meta-analyses of proportions to combine data and obtain summary estimates of the incidence of (a) SARS-CoV-2 re-infection, (b) severe COVID-19, (c) very severe/lethal COVID-19. We computed the pooled rate of each outcome twice: (1) using ≥ 45 days as the minimum time-lag between two positive episodes; (2) adopting a more stringent time-lag of ≥ 90 days ³⁹. Additionally, when data were available, we performed several stratified analyses and computed separate estimates by (a) gender; (b) exposure risk (healthcare workers vs. the general population); (c) vaccination status (unvaccinated; coverage of 25-50% of the sample; coverage of 100%); (d) dominant viral strain (Alpha or Beta; Delta; Omicron); (e) months between first episode and reinfection (< 6 ; 6-11; ≥ 12); (f) risk of reinfection misclassification. As the definition of reinfection has evolved over time ²⁸, some studies did not verify the presence of an intermediate negative RT-PCR sample or viral genomic sequencing data during the ≥ 45 days between the positive swabs. Since a new positive RT-PCR in a subject with a previously documented infection may indicate reinfection, but also persistence of non-viable RNA after the first episode - documented up to 104 days after the initial infection - or relapse ⁴¹, these studies were considered at risk of misclassification bias. All analyses were carried out using Stata, version 13.1 (Stata Corp., College Station, TX, 2013).

Results

Of the 3282 papers initially retrieved, we included 91 cohort studies evaluating the onset of reinfection, severe and very severe/lethal COVID-19 among 15,034,624 previously infected subjects (Figure 1), either among healthcare workers (27 publications; n=37,598^{2,8,9,15,17,24,36,38,42-59}) or in the general population (67 publications; n=14,997,026^{3-7,10,12,16-23,25,27,43,49,60-107}).

Four studies contributed with more than one dataset^{4,17,49,71}, as the same publication provided separate data both for staff and residents of long-term care facilities^{17,49}, or adopted different approaches to evaluate the baseline positivity in two separate groups of subjects⁴, finally provided individual participants data⁷¹. This led to a total of 94 datasets included in the analyses.

As shown in Table S1, most of the included studies (n=43) were carried out in Europe^{2,4-10,12,15,17,18,21,24,36,38,44,46-51,58,66,69,71,72,75,81,85-88,91-93,95,99,102,107}, 24 in the USA^{20,22,23,25,42,43,57,59,63,67,77,79,82-84,89,90,97,98,103,105,106,108}, 18 in Asia^{3,16,19,27,45,52-54,56,60,62,64,65,70,73,74,100,101}, and the remaining six in South America or South Africa^{61,68,80,94,96,104}. The mean age of the participants ranged from 15 to 87 years, and the average follow-up ranged from 29 to 371 days. Overall, 38 publications strictly followed the CDC criteria to identify the reinfections, and were classified at low risk of misclassification bias^{10,16,19,20,22-24,36,44,45,48-50,54,56,58,59,68,71,72,75,84,86,89-91,94,99,100,102,107}. All but five studies (n=3,854,961)^{66,71,88,91,96} were completed before the emergence of BA.1/B.1.1.529 (Omicron) variant. A total of 52 out of the 91 included studies reported an incidence of reinfections below 1%, and 47 an absolute risk of severe or lethal COVID-19 below 0.1%.

Overall, a total of 158,478 reinfections were recorded among the 15,034,624 subjects with a previous infection^{2-10,12,13,15-25,27,36,38,42-108}, corresponding to a pooled rate of 0.97% (95% CI: 0.71%-1.27% - Table 1; Figure 2). The summary rate of reinfection rose to 1.07% (95% CI: 0.73%-1.46%) when only the 69 datasets with a more conservative time-lag of ≥ 90 days between the two episodes were considered^{3-6,8-10,12,18-23,25,36,42-44,46-50,52-56,59,61-65,67-69,72-84,86,87,89,91-96,98,101,103,105-108} and it slightly varied by reinfection definition criteria (0.93% vs 1.01% when considering studies with high vs low risk of misclassification). The risk of reinfection was higher among healthcare workers as compared to the general population (1.20% vs 0.90%), and among females (0.79% vs 0.55% among males), although these estimates showed largely overlapping confidence intervals. Conversely, the reinfection rate varied widely by vaccination status: a lower likelihood of reinfection was observed in the studies where 100% of the subjects received at least one vaccine dose (0.32% vs. 0.77% among the unvaccinated - Table 1). Overall, the pooled rates of reinfection were higher in US-based studies (1.08%; 95% CI: 0.93%-1.25%) than in studies performed in Europe (0.63%; 95% CI: 0.44%-0.84%), or in Asia (0.77%; 95% CI: 0.50%-1.10%).

When the analyses were stratified by time from the primary infection, the highest reinfection rates were observed after 6-11 months from the first episode, reaching 1.12% (95% CI: 0.57%-1.82%); the pooled rates then substantially decreased to 0.66% after ≥ 12 months from the first infection.

Finally, when the analyses were stratified by predominant strain, a sharply rising trend was observed with the emergence of new variants: the pooled reinfection rates were 0.57% (95% CI: 0.28%-0.94%) in the studies

providing specific data on the Alpha wave; the rates rose to 1.25% (95% CI: 0.97%-1.55%) with the Delta strain, and peaked to 3.31% (95% CI: 1.15%-6.53%) during the first three months of the Omicron wave.

In the 59 available datasets ^{2,3,5,6,10,16-22,25,27,36,44,46-59,63-67,69,71-74,79,82,84-87,90,93-95,99-104,107}, a total of 1380 severe COVID-19 diseases were diagnosed among 5,006,604 subjects with a previous infection, corresponding to a pooled rate of 0.02% (95% CI: 0.00%-0.04% - Table 1). This rate did not substantially vary when only the studies with longer time-lag were considered, while it increased - still, however, remaining below 0.1% - when only the studies that used CDC criteria to define reinfections were included (summary rate 0.07%; 0.04%-0.10%). The risk of severe COVID-19 was always below 0.1% with any predominant strain and in the studies where 100% of the subjects received at least one vaccine dose (0.01% vs 0.10% among the unvaccinated - Table 1).

Finally, in the 54 datasets that provided data for the analysis of very severe/lethal COVID-19 ^{2,3,5,6,10,16-22,25,27,44,47-59,64-66,69,71-73,79,81,82,84-87,92,94,95,99-104,107}, a total of 199 events were recorded among 3,574,793 previously infected individuals, corresponding to a pooled rate of 0.02% (0.01%-0.03%), which did not differ by time-lag or definition criteria.

Discussion

The main findings of this meta-analysis, based upon the pooled results of 91 cohort studies, including more than 15 million individuals who were previously infected with SARS-CoV-2 provide some solid confirmations, and a few updates: (a) after an average of twelve months of follow-up, the overall risk of reinfection approaches 1%, with no substantial differences across genders, exposure risk, and definition criteria; (b) the likelihood of reinfection increased considerably over time, particularly with the spread of new highly transmissible variants, peaking during the first three months of the Omicron wave; (c) the summary rates of severe or lethal COVID-19 were still very low, ranging from 2 to 7 out of 10,000 subjects according to the adopted definition criteria, and were not affected by strain predominance; (d) the pooled risk of reinfection was significantly lower among the subjects that received one or more vaccine doses, versus the unvaccinated.

A low risk of reinfection, and a very low risk of severe or lethal COVID-19 for those who recovered from a primary infection, were reported in the vast majority of the published studies, as well in the available systematic reviews ¹⁰⁹⁻¹¹². Most of the available information, however, included data preceding the emergence of the Omicron wave ¹¹¹, or relied upon very preliminary data ¹⁰⁹. Importantly, we expanded the existing evidence with the analysis of a very large database across different geographic areas, including reinfections up to the first three months of the Omicron wave, and providing confirmation ⁹⁶ of a substantially increased risk of reinfection, temporally linked with the emergence of this variant.

In the context of the pandemic, there has been debate on the health policies to adopt for the population of previously infected subjects ^{40,113}. On one side, the restriction policies and vaccination requirements have been less strict in several countries, in consideration of their low/very low risk profile ¹¹⁴⁻¹¹⁶. On the other side, concerns on the appropriateness of such policies remained, because the duration of the natural

immunity was unknown and, more recently, because of the spread of the Omicron variant, which showed a marked increase in the number of infections and hospitalizations as a result of a very high level of community transmission ¹¹⁷⁻¹¹⁹. This led some countries to establish a time limit from the first infection, after which one or two doses of vaccine were requested ¹²⁰. However, data are strongly needed to support such policies, since no study evaluated the risk of reinfection after 12 months of follow-up, during the Omicron wave, and no information was available on the potential impact of vaccination after the first infection.

Some of the findings of our analysis are reassuring, supporting less strict, targeted policies for the subjects who recovered from a previous infection: the rates of severe or lethal COVID-19 were extremely low, suggesting that the health risk and impact on the health services of these subjects, during the next phases of the SARS-CoV-2 pandemic, might be very limited. On the other side, however, we observed a concerning, marked increase of the reinfection rates during the Omicron wave, and a significantly lower risk of reinfection among the vaccinated subjects, thus vaccinating also this population may definitely play an important role to control the pandemic. It remains to be considered that, if during the Omicron wave the risk of a secondary severe disease or death will remain close to zero despite the large increase of reinfections, the risk-benefit profile of multiple vaccine doses for this population will have to be carefully evaluated. Unfortunately, of the five studies providing data on the Omicron wave, only two (although based upon a very large sample) specifically assessed the number of severe COVID-19 ^{66,71}. On one side, the very low pooled rates of hospitalization recorded even after Omicron surge are reassuring. On the other side, however, such findings require confirmation, and the large increase of reinfections during the first months of Omicron predominance is a matter of serious concern.

Interestingly, and in line with previous studies ^{71,96}, we found some degree of variation in reinfection rates across geographical areas. Besides the genetic pattern, the main potential explanations include differences in the detection process caused by the adoption of diverse testing policies, diagnostic methods and health-seeking behaviors ^{65,96}, and the fact that countries have been sequentially hit by different variants of SARS-CoV-2 ¹²¹. Indeed, the mutual combination of these factors may explain, at least in part, the spatial unevenness of SARS-CoV-2 spread, which has been observed even at a sub-national level ^{96,122}.

The study has some limitations that should be considered when interpreting the results. On one side, the incidence of reinfection could have been overestimated in several of the included studies, which confirmed the reinfection status adopting less stringent definition criteria ³⁹. On the other side, the rate of reinfection may have been underestimated in most studies, as the existing monitoring systems could not detect all of the asymptomatic reinfections. Indeed, many subjects might not have sought medical attention because of mild or even sub-clinical disease. To address this potential detection bias, a sensitivity analysis based upon the average number of PCR tests performed, taken as a proxy of health-seeking behaviour, may have increased the precision of our estimates ⁷³. Unfortunately, these data were not available. Notably, however, the pooled estimates of reinfection incidence were comparable in the general population and healthcare workers, who have often been subjects to continuous testing ³⁸. Second, individual-participant data were available for one

study only ⁷¹, thus we could not perform stratified analyses based upon age, concomitant immunological conditions potentially affecting the risk of reinfection, or, as above said, health seeking behaviours ^{11,76}.

Acknowledging these caveats, the present meta-analysis showed that, among more than 15 million previously infected individuals, the overall rates of reinfection showed an increasing trend alongwith the emergence of Omicron variant, although the risk of severe or lethal COVID-19 was still very low, and vaccination may be effective in reducing the risk of reinfection. Further data from studies with even longer follow-up, carried out after the first months of the Omicron wave, and assessing whether the risk of severe or lethal COVID-19 will vary with the spread of new variants ¹²³, are inevitably needed to guide the future public health policies targeted to the large population of subjects who recovered from a SARS-CoV-2 infection.

References

1. To KK, Hung IF, Ip JD, et al. Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. *Clin Infect Dis*. Nov 2 2021;73(9):e2946-e2951. doi:10.1093/cid/ciaa1275 5897019 [pii]
2. Abo-Leyah H, Gallant S, Cassidy D, et al. The protective effect of SARS-CoV-2 antibodies in Scottish healthcare workers. *ERJ Open Res*. Apr 2021;7(2)doi:00080-2021 [pii] 10.1183/23120541.00080-2021
3. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA*. Nov 16 2021;326(19):1930-1939. doi:10.1001/jama.2021.19623
4. Breathnach AS, Duncan CJA, Bouzidi KE, et al. Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. *J Infect*. Aug 2021;83(2):237-279. doi:S0163-4453(21)00266-8 [pii] 10.1016/j.jinf.2021.05.024
5. Breathnach AS, Riley PA, Cotter MP, Houston AC, Habibi MS, Planche TD. Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. *J Infect*. Apr 2021;82(4):e11-e12. doi:S0163-4453(21)00010-4 [pii] 10.1016/j.jinf.2021.01.005
6. Brouqui P, Colson P, Melenotte C, et al. COVID-19 re-infection. *Eur J Clin Invest*. May 2021;51(5):e13537. doi:10.1111/eci.13537
7. Clarke CL, Predecki M, Dhutia A, et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. *Kidney Int*. Jun 2021;99(6):1470-1477. doi:S0085-2538(21)00295-7 [pii] 10.1016/j.kint.2021.03.009
8. Davido B, De Truchis P, Lawrence C, et al. SARS-CoV-2 reinfections among hospital staff in the greater Paris area. *J Travel Med*. Jun 1 2021;28(4)doi:taab058 [pii] 10.1093/jtm/taab058 6217507 [pii]
9. Dobano C, Ramirez-Morros A, Alonso S, et al. Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. *BMC Med*. Jun 28 2021;19(1):155. doi:10.1186/s12916-021-02032-2 10.1186/s12916-021-02032-2 [pii]
10. Fabianova K, Kyncl J, Vlckova I, et al. COVID-19 reinfections. *Epidemiol Mikrobiol Immunol*. Spring 2021;70(1):62-67. Reinfekce covidem-19. doi:126636 [pii]
11. Flacco ME, Acuti Martellucci C, Soldato G, et al. Rate of reinfections after SARS-CoV-2 primary infection in the population of an Italian province: a cohort study. *J Public Health (Oxf)*. Sep 8 2021;doi:fdab346 [pii] 10.1093/pubmed/fdab346 6366077 [pii]
12. Gautret P, Houhamdi L, Nguyen NN, Hoang VT, Giraud-Gatineau A, Raoult D. Does SARS-CoV-2 re-infection depend on virus variant? *Clin Microbiol Infect*. Sep 2021;27(9):1374-1375. doi:S1198-743X(21)00360-8 [pii] 10.1016/j.cmi.2021.06.029
13. Gazit S, Shlezinger, Perez G, al. e. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. *MedRxiv*. 2021;doi:https://doi.org/10.1101/2021.08.24.21262415
14. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
15. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *J Infect*. Apr 2021;82(4):e29-e30. doi:S0163-4453(20)30781-7 [pii] 10.1016/j.jinf.2020.12.023
16. Hussein NR, Rashad BH, Almizori LA, et al. The Risk of SARS-CoV-2 Reinfection in Duhok city, Kurdistan Region of Iraq. *Mediterr J Hematol Infect Dis*. 2021;13(1):e2021035. doi:10.4084/MJHID.2021.035

mjh13-1-e2021035 [pii]

17. Krutikov M, Palmer T, Tut G, et al. Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study. *Lancet Healthy Longev.* Jun 2021;2(6):e362-e370. doi:10.1016/S2666-7568(21)00093-3 S2666-7568(21)00093-3 [pii]
18. Leidi A, Koegler F, Dumont R, et al. Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study. *Clin Infect Dis.* May 27 2021;doi:ciab495 [pii] 10.1093/cid/ciab495 6287116 [pii]
19. Mukherjee A, Anand T, Agarwal A, et al. SARS-CoV-2 re-infection: development of an epidemiological definition from India. *Epidemiol Infect.* Mar 26 2021;149:e82. doi:10.1017/S0950268821000662 S0950268821000662 [pii]
20. Peltan ID, Beesley SJ, Webb BJ, et al. Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing. *PLoS One.* 2021;16(5):e0251214. doi:10.1371/journal.pone.0251214 PONE-D-21-03536 [pii]
21. Pilz S, Chakeri A, Ioannidis JP, et al. SARS-CoV-2 re-infection risk in Austria. *Eur J Clin Invest.* Apr 2021;51(4):e13520. doi:10.1111/eci.13520
22. Qureshi AI, Baskett WI, Huang W, Lobanova I, Naqvi SH, Shyu CR. Re-infection with SARS-CoV-2 in Patients Undergoing Serial Laboratory Testing. *Clin Infect Dis.* Apr 25 2021;doi:ciab345 [pii] 10.1093/cid/ciab345 6251701 [pii]
23. Rennert L, McMahan C. Risk of SARS-CoV-2 reinfection in a university student population. *Clin Infect Dis.* May 16 2021;doi:ciab454 [pii] 10.1093/cid/ciab454 6276528 [pii]
24. Sanchez-Montalva A, Fernandez-Naval C, Anton A, et al. Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure. *J Clin Med.* May 4 2021;10(9)doi:1968 [pii] 10.3390/jcm10091968 jcm10091968 [pii]
25. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clin Infect Dis.* Nov 16 2021;73(10):1882-1886. doi:10.1093/cid/ciab234 6170939 [pii]
26. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. *JAMA Intern Med.* Oct 1 2021;181(10):1407-1408. doi:10.1001/jamainternmed.2021.2959 2780557 [pii]
27. Zare F, Teimouri M, Khosravi A, et al. COVID-19 re-infection in Shahroud, Iran: a follow-up study. *Epidemiol Infect.* Apr 19 2021;149:e159. doi:10.1017/S095026882100087X S095026882100087X [pii]
28. Yahav D, Yelin D, Eckerle I, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. *Clin Microbiol Infect.* Mar 2021;27(3):315-318. doi:S1198-743X(20)30724-2 [pii] 10.1016/j.cmi.2020.11.028
29. Biswas S, Mahmud S, Mita MA, et al. The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. *Front Med (Lausanne).* 2022;9:825245. doi:10.3389/fmed.2022.825245
30. Akkiz H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. *Front Med (Lausanne).* 2022;9:849217. doi:10.3389/fmed.2022.849217
31. Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. *Environ Res.* Jun 2022;209:112911. doi:S0013-9351(22)00238-9 [pii] 10.1016/j.envres.2022.112911

32. Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. The Importance and Challenges of Identifying SARS-CoV-2 Reinfections. *J Clin Microbiol*. Mar 19 2021;59(4)doi:e02769-20 [pii] 10.1128/JCM.02769-20 [pii]
33. Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. *Nat Rev Immunol*. Jun 2021;21(6):395-404. doi:10.1038/s41577-021-00550-x 10.1038/s41577-021-00550-x [pii]
34. Worldometer. COVID-19 Coronavirus Outbreak. Accessed March 14, 2020. <https://www.worldometers.info/coronavirus/>
35. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. Mar 29 2021;372:n71. doi:10.1136/bmj.n71
36. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet*. Apr 17 2021;397(10283):1459-1469. doi:S0140-6736(21)00675-9 [pii] 10.1016/S0140-6736(21)00675-9
37. Carr D. Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak. Wellcome UK. Accessed May 11, 2020, <https://wellcome.ac.uk/coronavirus-covid-19/open-data>
38. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*. Feb 11 2021;384(6):533-540. doi:10.1056/NEJMoa2034545
39. Common Investigation Protocol for Investigating Suspected SARS-CoV-2 Reinfection (2020).
40. Jain VK, Iyengar K, Garg R, Vaishya R. Elucidating reasons of COVID-19 re-infection and its management strategies. *Diabetes Metab Syndr*. May-Jun 2021;15(3):1001-1006. doi:S1871-4021(21)00146-6 [pii] 10.1016/j.dsx.2021.05.008
41. Al-Tawfiq JA, Rabaan AA, Al-Omari A, Al Mutair A, Al-Qahtani M, Tirupathi R. Learning from SARS and MERS: COVID-19 reinfection where do we stand? *Travel Med Infect Dis*. May-Jun 2021;41:102024. doi:S1477-8939(21)00065-X [pii] 10.1016/j.tmaid.2021.102024
42. Akinbami LJ, Biggerstaff BJ, Chan PA, McGibbon E, Pathela P, Petersen LR. Reinfection with SARS-CoV-2 among previously infected healthcare personnel and first responders. *Clin Infect Dis*. Nov 15 2021;doi:ciab952 [pii] 10.1093/cid/ciab952 6428613 [pii]
43. Biggerstaff BJ, Akinbami LJ, Hales C, Chan PA, Petersen LR. Duration of Viral Nucleic Acid Shedding and Early Reinfection With Severe Respiratory Syndrome Coronavirus 2 in Healthcare Workers and First Responders. *J Infect Dis*. Dec 1 2021;224(11):1873-1877. doi:10.1093/infdis/jiab504 6381635 [pii]
44. Comelli A, Consonni D, Lombardi A, et al. Nasopharyngeal Testing among Healthcare Workers (HCWs) of a Large University Hospital in Milan, Italy during Two Epidemic Waves of COVID-19. *International journal of environmental research and public health*. Aug 19 2021;18(16)doi:8748 [pii] 10.3390/ijerph18168748 10.3390/ijerph18168748 [pii]
45. Dhumal S, Patil A, More A, et al. SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. *Int J Infect Dis*. May 2022;118:95-103. doi:S1201-9712(22)00115-1 [pii] 10.1016/j.ijid.2022.02.037
46. Dimeglio C, Herin F, Miedouge M, Martin-Blondel G, Soulat JM, Izopet J. Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection. *Clin Infect Dis*. Oct 5 2021;73(7):1323-1324. doi:10.1093/cid/ciab069 6121509 [pii]
47. Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*. Sep 2021;71:103561. doi:S2352-3964(21)00354-6 [pii] 10.1016/j.ebiom.2021.103561

48. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med*. Mar 31 2022;386(13):1207-1220. doi:10.1056/NEJMoa2118691
49. Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. *Lancet Healthy Longev*. Dec 2021;2(12):e811-e819. doi:10.1016/S2666-7568(21)00253-1
S2666-7568(21)00253-1 [pii]
50. Kohler P, Gusewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. *BMC Med*. Oct 14 2021;19(1):270. doi:10.1186/s12916-021-02144-9
10.1186/s12916-021-02144-9 [pii]
51. Leidi A, Berner A, Dumont R, et al. Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge: a cohort study. *Occup Environ Med*. Feb 2022;79(2):116-119. doi:10.1136/oemed-2021-107924
oemed-2021-107924 [pii]
52. Malhotra S, Mani K, Lodha R, et al. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. *JAMA Netw Open*. Jan 4 2022;5(1):e2142210. doi:10.1001/jamanetworkopen.2021.42210
2787712 [pii]
53. Murugesan M, Mathews P, Paul H, Karthik R, Mammen JJ, Rupali P. Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. *PLoS One*. 2022;17(5):e0268797. doi:10.1371/journal.pone.0268797
PONE-D-21-35055 [pii]
54. Nisha B, Dakshinamoorthy K, Padmanaban P, Jain T, Neelavarnan M. Infection, reinfection, and postvaccination incidence of SARS-CoV-2 and associated risks in healthcare workers in Tamil Nadu: A retrospective cohort study. *J Family Community Med*. Jan-Apr 2022;29(1):49-55. doi:10.4103/jfcm.jfcm_399_21
JFCM-29-49 [pii]
55. Racine E, Boivin G, Longtin Y, et al. The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. *Influenza Other Respir Viruses*. May 5 2022;doi:10.1111/irv.12997
56. Rahman S, Rahman MM, Miah M, et al. COVID-19 reinfections among naturally infected and vaccinated individuals. *Sci Rep*. Jan 26 2022;12(1):1438. doi:10.1038/s41598-022-05325-5
10.1038/s41598-022-05325-5 [pii]
57. Schuler CF, Gherasim C, O'Shea K, et al. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies. *Microbiol Spectr*. Oct 31 2021;9(2):e0008721. doi:10.1128/Spectrum.00087-21
58. Wack M, Pere H, Demory-Guinet N, et al. No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris. *J Clin Virol*. Dec 2021;145:104999. doi:10.1016/j.jcv.2021.104999
10.1016/j.jcv.2021.104999
59. Wilkins JT, Hirschhorn LR, Gray EL, et al. Serologic Status and SARS-CoV-2 Infection over 6 Months of Follow Up in Healthcare Workers in Chicago: A Cohort Study. *Infect Control Hosp Epidemiol*. Aug 9 2021;1-9. doi:10.1017/ice.2021.367
S0899823X21003676 [pii]
60. Ahmad HA, Khan H, Shahzad M, Haq ZU, Harakeh S, Yousafzai YM. Suspected reinfections of SARS-COV-2 in Khyber Pakhtunkhwa, Pakistan - analysis of province-wide testing database. *J Infect*. Oct 9 2021;doi:S0163-4453(21)00503-X [pii]
10.1016/j.jinf.2021.10.005
61. Akpan GE, Bawo L, Amo-Addae M, et al. COVID-19 reinfection in Liberia: Implication for improving disease surveillance. *PLoS One*. 2022;17(3):e0265768. doi:10.1371/journal.pone.0265768
PONE-D-21-36066 [pii]
62. Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19. *New Microbes New Infect*. Sep 2021;43:100926. doi:10.1016/j.nmni.2021.100926
S2052-2975(21)00090-1 [pii]

63. Armstrong JN, Campbell L, Rabatsky-Her T, Leung V, Parikh S. Repeat positive SARS-CoV-2 RNA testing in nursing home residents during the initial 9 months of the COVID-19 pandemic: an observational retrospective analysis. *Lancet Reg Health Am.* Nov 2021;3:100054. doi:10.1016/j.lana.2021.100054 S2667-193X(21)00046-6 [pii]
64. Arslan F, Isik Goren B, Baysal B, Vahaboglu H. Is vaccination necessary for COVID-19 patients? A retrospective cohort study investigating reinfection rates and symptomatology in a tertiary hospital. *Expert Rev Vaccines.* Dec 7 2021;1-4. doi:10.1080/14760584.2022.2012457
65. Arslan Y, Akgul F, Sevim B, Varol ZS, Tekin S. Re-infection in COVID-19: Do we exaggerate our worries? *Eur J Clin Invest.* Jun 2022;52(6):e13767. doi:10.1111/eci.13767
66. Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. *Lancet Infect Dis.* Jul 2022;22(7):967-976. doi:S1473-3099(22)00154-2 [pii] 10.1016/S1473-3099(22)00154-2
67. Bean DJ, Monroe J, Turcinovic J, Moreau Y, Connor JH, Sagar M. SARS-CoV-2 reinfection associates with unstable housing and occurs in the presence of antibodies. *Clin Infect Dis.* Nov 10 2021;doi:ciab940 [pii] 10.1093/cid/ciab940 6424810 [pii]
68. Cohen C, Kleynhans J, von Gottberg A, et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. *Lancet Infect Dis.* Jun 2022;22(6):821-834. doi:S1473-3099(22)00069-X [pii] 10.1016/S1473-3099(22)00069-X
69. Coppola A, Buonerba C, Cardinale D, et al. Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up. *Front Public Health.* 2021;9:801609. doi:10.3389/fpubh.2021.801609
70. Doke P, Gothankar JS, Doke PP, et al. Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection. *Microbes Infect.* Jun 2022;24(4):104979. doi:S1286-4579(22)00049-1 [pii] 10.1016/j.micinf.2022.104979
71. Flacco ME, Soldato G, Acuti Martellucci C, et al. Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study. *Front Public Health.* 2022;10:884121. doi:10.3389/fpubh.2022.884121
72. Garcia-Abellan J, Padilla S, Fernandez-Gonzalez M, et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. *J Clin Immunol.* Oct 2021;41(7):1490-1501. doi:10.1007/s10875-021-01083-7 10.1007/s10875-021-01083-7 [pii]
73. Gazit S, Shlezinger R, Perez G, et al. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study. *Ann Intern Med.* May 2022;175(5):674-681. doi:10.7326/M21-4130
74. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *N Engl J Med.* Jun 9 2022;386(23):2201-2212. doi:10.1056/NEJMoa2118946
75. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public Health.* May 2021;6(5):e335-e345. doi:S2468-2667(21)00055-4 [pii] 10.1016/S2468-2667(21)00055-4
76. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *Lancet.* Mar 27 2021;397(10280):1204-1212. doi:S0140-6736(21)00575-4 [pii] 10.1016/S0140-6736(21)00575-4
77. Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Internal Medicine.* May 1 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366 2776810 [pii]

78. Honge BL, Hindhede L, Kaspersen KA, et al. Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection. *Int J Infect Dis*. Mar 2022;116:289-292. doi:S1201-9712(22)00046-7 [pii] 10.1016/j.ijid.2022.01.041
79. Kim P, Gordon SM, Sheehan MM, Rothberg MB. Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study. *Clin Infect Dis*. Dec 3 2021;doi:ciab999 [pii] 10.1093/cid/ciab999 6448857 [pii]
80. Kubale J, Balmaseda A, Frutos AM, et al. Burden of SARS-CoV-2 and protection from symptomatic second infection in children. *MedRxiv*. Jan 5 2022;doi:2022.01.03.22268684 [pii] 10.1101/2022.01.03.22268684
81. Lacy J, Mensah A, Simmons R, et al. Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. *Epidemiol Infect*. May 24 2022;150:e109. doi:10.1017/S0950268822000966 S0950268822000966 [pii]
82. Lawandi A, Warner S, Sun J, et al. Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021. *Clin Infect Dis*. Apr 28 2022;74(8):1489-1492. doi:10.1093/cid/ciab671 6342166 [pii]
83. Leon TM, Dorabawila V, Nelson L, et al. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. *MMWR Morb Mortal Wkly Rep*. Jan 28 2022;71(4):125-131. doi:10.15585/mmwr.mm7104e1
84. Liu D, Rodriguez GD, Zhou HY, et al. SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection. *Int J Mol Sci*. Jun 2 2022;23(11)doi:6254 [pii] 10.3390/ijms23116254 ijms23116254 [pii]
85. Manica M, Pancheri S, Poletti P, et al. Risk of Symptomatic Infection During a Second Coronavirus Disease 2019 Wave in Severe Acute Respiratory Syndrome Coronavirus 2-Seropositive Individuals. *Clin Infect Dis*. Mar 9 2022;74(5):893-896. doi:10.1093/cid/ciab556 6301134 [pii]
86. Masia M, Padilla S, Galiana A, Fernandez-Gonzalez M, Gutierrez F. Incidence of delayed asymptomatic COVID-19 recurrences in a 6-month longitudinal study. *J Infect*. Jun 2021;82(6):276-316. doi:S0163-4453(21)00152-3 [pii] 10.1016/j.jinf.2021.03.020
87. Mensah AA, Campbell H, Stowe J, et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. *Lancet Child Adolesc Health*. Jun 2022;6(6):384-392. doi:S2352-4642(22)00059-1 [pii] 10.1016/S2352-4642(22)00059-1
88. Monge S, Rojas-Benedicto A, Olmedo C, et al. Effectiveness of a second dose of an mRNA vaccine against SARS-CoV-2 Omicron infection in individuals previously infected by other variants. *Clin Infect Dis*. Jun 10 2022;doi:ciac429 [pii] 10.1093/cid/ciac429 6605647 [pii]
89. Morris CP, Luo CH, Sachithanandham J, et al. Large Scale SARS-CoV-2 Molecular Testing and Genomic Surveillance Reveal Prolonged Infections, Protracted RNA shedding, and Viral Reinfections. *Front Cell Infect Microbiol*. 2022;12:809407. doi:10.3389/fcimb.2022.809407
90. Morris S, Anjan S, Pallikkuth S, et al. Reinfection with SARS-CoV-2 in solid-organ transplant recipients: Incidence density and convalescent immunity prior to reinfection. *Transpl Infect Dis*. Jun 2022;24(3):e13827. doi:10.1111/tid.13827
91. Nguyen NN, Houhamdi L, Hoang VT, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. *J Infect*. Apr 23 2022;doi:S0163-4453(22)00216-X [pii] 10.1016/j.jinf.2022.04.034
92. Nitipir C, Parosanu AI, Olaru M, et al. Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study. *Exp Ther Med*. Jun 2022;23(6):399. doi:10.3892/etm.2022.11326

ETM-23-6-11326 [pii]

93. Nordstrom P, Ballin M, Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. *Lancet Infect Dis*. Jun 2022;22(6):781-790. doi:S1473-3099(22)00143-8 [pii]
10.1016/S1473-3099(22)00143-8
94. Pampa-Espinoza L, Padilla-Rojas C, Silva-Valencia J, et al. Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections After a Second Wave With Predominance of Lambda in Lima and Callao, Peru. *Open Forum Infect Dis*. Jun 2022;9(6):ofac134. doi:10.1093/ofid/ofac134
ofac134 [pii]
95. Peghin M, Bouza E, Fabris M, et al. Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19. *Eur J Clin Microbiol Infect Dis*. Dec 2021;40(12):2597-2604. doi:10.1007/s10096-021-04335-x
10.1007/s10096-021-04335-x [pii]
96. Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. *MedRxiv*. 2021;doi:https://doi.org/10.1101/2021.11.11.21266068
97. Reynolds SL, Kaufman HW, Meyer WA, et al. Duration of Protection Against SARS-CoV-2 Reinfection and Associated Risk of Reinfection Assessed with Real-World Data. *MedRxiv*. Feb 26 2022;doi:2022.02.25.22271515 [pii]
10.1101/2022.02.25.22271515
98. Ridgway JP, Tideman S, Wright B, Robicsek A. Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19. *JAMA Netw Open*. Apr 1 2022;5(4):e227650. doi:10.1001/jamanetworkopen.2022.7650
2791312 [pii]
99. Rodriguez-Grande C, Alcalá L, Estevez A, et al. Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain. *Emerg Infect Dis*. Jan 2022;28(1):85-94. doi:10.3201/eid2801.211952
100. Salehi-Vaziri M, Pouriayevali MH, Fotouhi F, et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. *Microb Pathog*. Dec 2021;161(Pt B):105296. doi:S0882-4010(21)00570-2 [pii]
10.1016/j.micpath.2021.105296
101. Shaheen NA, Sambas R, Alenezi M, Alharbi NK, Aldibasi O, Bosaeed M. COVID-19 reinfection: A multicenter retrospective study in Saudi Arabia. *Ann Thorac Med*. Apr-Jun 2022;17(2):81-86. doi:10.4103/atm.atm_74_22
ATM-17-81 [pii]
102. Shankar S, Beckett J, Tipton T, et al. SARS-CoV-2-Specific T Cell Responses Are Not Associated with Protection against Reinfection in Hemodialysis Patients. *J Am Soc Nephrol*. May 2022;33(5):883-887. doi:10.1681/ASN.2021121587
ASN.2021121587 [pii]
103. Slezak J, Bruxvoort K, Fischer H, Broder B, Ackerson B, Tartof S. Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. *Clin Microbiol Infect*. Dec 2021;27(12):1860 e7-1860 e10. doi:S1198-743X(21)00422-5 [pii]
10.1016/j.cmi.2021.07.030
104. Smolenov I, Han HH, Li P, et al. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. *Lancet Infect Dis*. Jul 2022;22(7):990-1001. doi:S1473-3099(22)00144-X [pii]
10.1016/S1473-3099(22)00144-X
105. Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) - Kentucky, USA, 2020. *Int J Infect Dis*. Jan 2022;114:21-28. doi:S1201-9712(21)00800-6 [pii]
10.1016/j.ijid.2021.10.010
106. Spicer KB, Glick C, Cavanaugh AM, Thoroughman D. Association of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or a Prior Positive Test Result in Adolescents during the Delta Variant Surge in Kentucky. *J Pediatr*. May 27 2022;doi:S0022-3476(22)00486-3 [pii]
10.1016/j.jpeds.2022.05.034

107. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. *JAMA Intern Med.* May 28 2021;doi:10.1001/jamainternmed.2021.2959 2780557 [pii]
108. Rivelli A, Fitzpatrick V, Blair C, Copeland K, Richards J. Incidence of COVID-19 reinfection among Midwestern healthcare employees. *PLoS One.* 2022;17(1):e0262164. doi:10.1371/journal.pone.0262164 PONE-D-21-26814 [pii]
109. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection. *Ann Intern Med.* Jan 25 2022;doi:10.7326/M21-4245
110. Mao Y, Wang W, Ma J, Wu S, Sun F. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. *Chin Med J (Engl).* Dec 13 2021;135(2):145-152. doi:10.1097/CM9.0000000000001892 00029330-900000000-98270 [pii]
111. Chivese T, Matiznadzo JT, Musa OAH, et al. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis. *Pathog Glob Health.* Jul 2022;116(5):269-281. doi:10.1080/20477724.2022.2029301
112. Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. *Journal of medical virology.* Jan 2022;94(1):44-53. doi:10.1002/jmv.27281
113. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. *Lancet Infect Dis.* Jan 2022;22(1):12-14. doi:S1473-3099(21)00676-9 [pii] 10.1016/S1473-3099(21)00676-9
114. European Council. Council Recommendation on a coordinated approach to facilitate safe free movement during the COVID-19 pandemic and replacing Recommendation (EU) 2020/1475. In: Council E, editor. Brussels2022.
115. Italian Government. Misure urgenti per il contenimento della diffusione dell'epidemia da COVID-19 e disposizioni in materia di sorveglianza sanitaria. (21G00258). In: Government I, editor. 229 G.U. Serie Generale n.309, December 30, 20212021.
116. Dolgin E. Is one vaccine dose enough if you've had COVID? What the science says. *Nature.* Jul 2021;595(7866):161-162. doi:10.1038/d41586-021-01609-4 10.1038/d41586-021-01609-4 [pii]
117. Majeed A. London is an important barometer for the omicron wave in the United Kingdom. *BMJ.* Jan 11 2022;376:o42. doi:10.1136/bmj.o42
118. WHO. *Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States.* 2022. *Enhancing response to Omicron SARS-CoV-2 variant.* January 21, 22. Accessed January 16, 2022. [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-technical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
119. Willyard C. What the Omicron wave is revealing about human immunity. *Nature.* Feb 2022;602(7895):22-25. doi:10.1038/d41586-022-00214-3 10.1038/d41586-022-00214-3 [pii]
120. Italian Ministry of Health. Aggiornamento indicazioni sulla Vaccinazione dei soggetti che hanno avuto un'infezione da SARS-CoV-2. In: Italian Ministry of Health, editor. 2021.
121. Prajapat M, Handa V, Sarma P, et al. Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. *Indian J Pharmacol.* Jul-Aug 2021;53(4):310-316. doi:10.4103/ijp.ijp_483_21 Indian J Pharmacol_2021_53_4_310_324046 [pii]
122. Ascani A, Faggian A, Montresor S. The geography of COVID-19 and the structure of local economies: The case of Italy. *J Reg Sci.* Dec 21 2020;doi:10.1111/jors.12510 JORS12510 [pii]
123. Callaway E. Are COVID surges becoming more predictable? New Omicron variants offer a hint. *Nature.* May 2022;605(7909):204-206. doi:10.1038/d41586-022-01240-x 10.1038/d41586-022-01240-x [pii]

Table 1. Pooled rates of reinfection ^A, severe COVID-19 disease ^B and very severe/lethal COVID-19 ^C among subjects with a previous SARS-CoV-2 infection, overall and according to re-infection definition criteria, gender, exposure risk (type of population), time-lag between first infection and second episode, vaccination status and predominant strain. Data from single studies have been combined using proportion meta-analysis (random-effect model).

<i>Outcomes</i>	<i>Study ref. *</i>	<i>N. datasets* (raw data)</i>	<i>Pooled rates, % (95% CI)</i>	<i>I, %</i>
Reinfection ^A				
- Estimated pooled rate	2-10,12,13,15-25,27,36,38,42-108	94 (158,478 / 15,034,624)	0.97 (0.71-1.27)	99
- Including only studies with time-lag ≥90 days **	3-6,8-10,12,18-23,25,36,42-44,46-50,52-56,59,61-65,67-69,72-84,86,87,89,91-96,98,101,103,105-108	69 (142,596 / 11,895,618)	1.07 (0.73-1.46)	99
<u>Stratified analyses:</u>				
<i>1. By reinfection definition criteria:</i>				
- Probable reinfection (high risk of misclassification) ^D	2,4,5,7-9,12,15,17,18,21,25,27,38,42,46,47,51-53,55,57,60,62,64-66,69,70,73,74,76-83,85,87,88,92,93,95-98,101,103-106,108	56 (155,051 / 12,868,418)	0.93 (0.64-1.28)	99
- Confirmed reinfection (low risk of misclassification) ^E	10,16,19,20,22-24,36,44,45,48-50,54,56,58,59,68,71,72,75,84,86,88,89-91,94,99,100,102,107	38 (3427 / 2,166,206)	1.01 (0.61-1.49)	99
<i>2. By gender:</i>				
- Males	5,9,18,22,36,42,47,49-51,55-57,59,65,69-72,74,82,86,87,93,95,96,102,103,105,108	32 (47,969 / 2,634,694)	0.55 (0.14-1.16)	99
- Females	5,9,18,22,36,42,47,49-51,55-57,59,65,69-72,74,82,86,87,93,95,96,102,103,105,109	32 (70,099 / 7,695,452)	0.79 (0.18-1.69)	99
<i>3. By exposure risk:</i>				
- General population	3-7,10,12,13,16-23,25,27,49,60,62-64,67,69,72,75-77,86,95,99,100,103,105,107	67 (157,806 / 14,997,026)	0.90 (0.61-1.24)	99
- Healthcare workers	2,8,9,15,17,24,36,38,42-59	27 (672 / 37,598)	1.20 (0.59-1.98)	92
<i>4. By length of follow-up (time between first infection and reinfection):</i>				
- Less than 6 months (<183 days)	3,6,7,15-17,19,20,22-25,27,38,46,49,57,63,67,70,71,73,75-77,83,84,88,93,97,98,108	34 (35,487 / 8,123,293)	0.58 (0.50-0.68)	99
- 6-11 months (183-364 days)	2,9,10,18,21,36,42,44,45,50-52,54,59,61,65,71,79,86,90,91,94,95,102,103,106,107	27 (3146 / 1,987,532)	1.12 (0.57-1.82)	99
- 12 or more months (≥365 days)	8,55,71	4 (362 / 48,384)	0.66 (0.50-0.84)	24

Table 1 (cont.).

Outcomes	Study ref. *	N. datasets* (raw data)	Pooled rates, % (95% CI)	I, %
5. By vaccination status:				
- Unvaccinated	49-51,55,57,63,68,71,93,97,98,102,104	14 (12,408 / 3,116,047)	0.74 (0.57-0.93)	99
- Vaccination campaign covering 25-50% of the sample	36,47,54,56,74,79,83,94,105	9 (21,800 / 5,727,836)	0.95 (0.45-1.64)	99
- Vaccination campaign covering 100% of the sample	3,71	3 (588 / 248,049)	0.32 (0.11-0.64)	99
6. By predominant viral strain:^F				
- Alpha (B.1.1.7)	3,8,17,47,49,71,81,87,90,104	11 (5566 / 1,209,861)	0.57 (0.28-0.94)	99
- Delta (B.1.617.2)	30,45,52,53,56,65,70,73,74,79,80,83,89,93,106	15 (26,583 / 5,225,116)	1.25 (0.97-1.55)	100
- Omicron (B.1.1.529)	66,71,88,91,96	5 (112,928 / 3,854,961)	3.31 (1.15-6.53)	99
7. By geographic area:				
- Europe	2,4-10,12,15,17,18,21,24,36,38,44,46-51,58,66,69,71,72,75,81,85-88,91-93,95,99,102,107	46 (17,186 / 3,263,398)	0.63 (0.44-0.84)	100
- US	20,22,23,25,42,43,57,59,63,67,77,79,82-84,89,90,97,98,103,105,106,108,109	24 (28,136 / 6,119,540)	1.08 (0.93-1.25)	99
- Asia	3,16,19,27,45,52-54,56,60,62,64,65,70,73,74,100,101	18 (8161 / 1,063,517)	0.77 (0.50-1.10)	99
Severe COVID-19 disease ^B				
- Estimated pooled rate	2,3,5,6,10,16-22,25,27,36,44,46-59,63-67,69,71-74,79,82,84-87,90,93-95,99-104,107	59 (1380 / 5,006,604)	0.02 (0.00-0.04)	98
- Including only studies with time-lag ≥90 days **	3,5,6,10,18-22,25,36,44,46-50,52-56,59,63-65,67,69,72-74,79,82,84,86,87,90,93-95,103,107	44 (1322 / 4,785,454)	0.02 (0.00-0.06)	99
Stratified analyses:				
1. By reinfection definition criteria:				
- Probable reinfection (high risk of misclassification) ^D	2,5,17,18,21,25,27,46,47,51-53,55,57,64-66,69,73,74,79,82,85,87,93,95,101,103,104	30 (1282 / 2,907,510)	0.05 (0.01-0.10)	99
- Confirmed reinfection (low risk of misclassification) ^E	3,6,10,16,19,20,22,36,44,48-50,54,56,58,59,63,67,71,72,84,86,90,94,99,100,102,107	29 (98 / 2,099,094)	0.07 (0.04-0.10)	93

Table 1 (cont.).

<i>Outcomes</i>	Study ref. *	N. datasets* (raw data)	Pooled rates, % (95% CI)	I, %
<i>2. By vaccination status:</i>				
- Unvaccinated	49-51,55,57,63,71,93,102,104	11 (164 / 1,066,987)	0.10 (0.04-0.19)	86
- Vaccination campaign covering 25-50% of the sample	36,47,54,56,74,79,94	7 (43 / 2,371,936)	0.00 (0.00-0.01)	95
- Vaccination campaign covering 100% of the sample	3,48,71	3 (17 / 248,049)	0.01 (0.00-0.03)	93
<i>3. By predominant viral strain:^F</i>				
- Alpha (B.1.1.7)	3,17,47,49,71,87,90,104	9 (88 / 950,690)	0.03 (0.01-0.06)	92
- Delta (B.1.617.2)	52,53,56,65,73,74,79,93	8 (1087 / 1,862,216)	0.07 (0.00-0.20)	100
- Omicron (B.1.1.529)	66,71	2 (19 / 64,522)	0.03 (0.02-0.04)	--
Very severe/lethal COVID-19 ^C				
- Estimated pooled rate	2,3,5,6,10,16-22,25,27,44,47-59,64-66,69,71-73,79,81,82,84-87,92,94,95,99-104,107	54 (199 / 3,574,793)	0.02 (0.00-0.03)	91
- Including only studies with time-lag ≥90 days **	3,5,6,10,18-22,25,44,47-50,52-56,59,64,65,67,69,72,73,79,81,82,84,86,87,94,95,101,103,107	39 (183 / 3,392,229)	0.02 (0.01-0.03)	93
<u>Stratified analyses:</u>				
<i>1. By reinfection definition criteria:</i>				
- Probable reinfection (high risk of misclassification) ^D	2,5,17,18,21,25,27,47,51-53,55,57,64,65,69,73,79,81,82,85,87,92,95,101,103,104	28 (171 / 1,490,266)	0.02 (0.01-0.03)	92
- Confirmed reinfection (low risk of misclassification) ^E	3,6,10,16,19,20,22,44,48-50,54,56,58,59,67,71,72,84,86,94,99,100,102,107	26 (28 / 2,084,527)	0.02 (0.01-0.03)	92

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus; CI: Confidence interval. Raw data show the number of subjects with each outcome upon the total number of included subjects.

^A Asymptomatic infection or mild disease, defined as fever or malaise plus at least one of the followings: sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis, and diarrhea with no hospital admission.

^B Severe disease, requiring hospital admission, not in an intensive care unit.

^c Very severe or lethal disease, requiring admission in an intensive care unit and/or causing death.

* Four studies ^{4,17,49,71} contributed with more than one dataset, thus the number of references does not always match the number of datasets included in each analysis (see methods for further details).

** Excluding studies with a time-lag <90 days between two positive RT-PCR tests, with or without an intermediate negative PCR/viral genomic confirmation between the first and second episode.

^D A probable reinfection was defined as new positive RT-PCR sample ≥ 45 days after a proven baseline SARS-CoV-2 infection (either assessed through a first positive nasopharyngeal swab or a positive serology- detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay- ELISA), with no intermediate negative RT-PCR sample or viral genomic sequencing.

^E A confirmed reinfection was defined as a new positive RT-PCR sample ≥ 45 days after a proven baseline SARS-CoV-2 infection (either assessed through a first positive nasopharyngeal swab or a positive serology- detection of anti-S1 domain of spike protein IgG antibodies using an enzyme-linked immunosorbent assay - ELISA), with ≥ 1 intermediate negative RT-PCR sample and/or a confirmation of infection with two different phylogenetic strains, obtained through viral genomic sequencing.

^F Alpha wave: from September 2020 (first detection: UK; worldwide geographic distribution); Delta wave: from December 2020 (first detection: India; worldwide geographic distribution); Omicron wave: from December 2021 (first detection: South Africa; worldwide geographic distribution); Available in: <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>. For Italy: Omicron wave started from December 28, 2021 when the proportion of Omicron variant in the available positive swabs was higher than 50%. Available in: Italian National Institute of Health (2021) Stima della prevalenza delle varianti VOC (Variants of Concern) in Italia: beta, gamma, delta, omicron e altre varianti di SARS-CoV-2.

(https://www.iss.it/documents/20126/0/Report_flashVarianti_14gennaio22.pdf/b44b1a7d-a0c1-67fd-44b7-34c8b775c088?t=1642162662435)




Figure 1. PRISMA 2020 flow diagram.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71




Figure 2. Proportion meta-analysis of the risk of SARS-CoV-2 reinfection among previously infected subjects.

Figure legends

Figure 1. PRISMA 2020 flow diagram.

Figure 2. Proportion meta-analysis of the risk of SARS-CoV-2 reinfection among previously infected subjects.